(Press-News.org) Most detailed study to date including 345,000 people from 48 randomised clinical trials finds that blood pressure-lowering medication is effective in adults regardless of starting blood pressure level.
Each 5mmHg reduction in systolic blood pressure lowered the relative risk of cardiovascular events by around 10%, even in people with normal blood pressure and those who had never had a heart attack or stroke.
Authors call for global guidelines to be changed so that anyone with increased risk of cardiovascular disease is considered for blood-pressure lowering medication, irrespective of their blood pressure.
Blood pressure-lowering medication can prevent serious cardiovascular conditions such as strokes, heart failure and heart attacks even in adults with normal blood pressure, according to new research published in The Lancet.
Importantly, the study found the beneficial effects of treatment were similar regardless of the starting blood pressure level, in both people who had previously had a heart attack or stroke and in those who had never had heart disease.
The authors say that the findings have immediate and important implications for global clinical guidelines that typically limit blood pressure-lowering treatment to individuals with high blood pressure (usually above 140/90 mmHg).
"Our findings are of great importance to the debate concerning blood pressure treatment", says lead author Professor Kazem Rahimi, University of Oxford, UK. "This new and best available evidence tells us that decisions to prescribe blood pressure medication should not be based simply on a prior diagnosis of cardiovascular disease or an individual's blood pressure level. Instead, medication should be viewed as an effective tool for preventing cardiovascular disease in people at increased risk of developing heart disease or stroke. Clinical guidelines should be changed to reflect these findings." [1]
He cautions, "We're not saying that everyone must begin treatment. The decision will depend on an individual's risk factors for developing cardiovascular disease, the potential for side effects and patient choice." [1]
Heart disease and stroke, linked to high blood pressure, are the leading cause of death across most of the western world. It is widely accepted that blood pressure medication protects people who have had a prior heart attack or stroke from having a second, but the use of these drugs in people with normal or mildly elevated blood pressure has been debated [2]. So far, studies examining whether blood pressure-lowering medication is equally beneficial in people with and without a history of cardiovascular disease, and at lower blood pressure levels than currently considered for treatment (typically 140/90 mmHg or higher) have reported conflicting findings. This has led to contradictory treatment recommendations around the world.
For the current analysis, the Blood Pressure Lowering Treatment Triallists' Collaborators pooled data from 344,716 adults (average age 65 years) in 48 randomised trials (the gold standard for evaluating the effectiveness of treatments) to explore the effects of blood pressure-lowering medications. Participants were separated into two groups: those with a prior diagnosis of cardiovascular disease (157,728 participants - secondary prevention group) and those without (186,988 - primary prevention group, without cardiovascular disease).
Each group was then divided into seven subgroups based on levels of systolic blood pressure at study entry (less than 120, 120-129, 130-139, 140-149, 150-159, 160-169, 170 and above mmHg). Around 20% (31,239) of participants with prior cardiovascular disease and 8% (14,928) of those who had never had cardiovascular disease had normal or high-normal systolic blood pressure at the start of the trials (systolic blood pressure less than 130 mmHg).
Over an average of four years follow-up, 42,324 participants had at least one major cardiovascular event (heart attack, stroke, heart failure, or death from cardiovascular disease). For every 5 mmHg reduction in systolic blood pressure, the risk of developing major cardiovascular disease fell by around 10% (18,287 vs 24,037 major cardiovascular disease in the intervention and comparator groups, respectively), stroke by 13% (6,005 vs 7,767), heart failure by 13% (3,249 vs 4,584), ischaemic heart disease by 8% (8,307 vs 11,145), and death from cardiovascular disease by 5% (4,825 vs 6,110).
The beneficial effects of the treatment did not differ based on a history of having had cardiovascular disease or the level of blood pressure at study entry.
"It is important that people are considered for blood pressure-lowering treatment based on their cardiovascular risk, rather than focusing on blood pressure itself as a qualifying factor for or target of treatment," says co-author Zeinab Bidel from the University of Oxford, UK. "We must provide well-rounded guidelines to lower risks for cardiovascular disease that include exercise, nutrition, smoking cessation, and - where appropriate - medication." [1]
The study has some limitations including that it only investigated the impact of starting blood pressure and prior cardiovascular disease on treatment effects, so the findings cannot be generalised to other patient characteristics that we have not included in our analysis. Additionally, the effects on diseases other than major cardiovascular disease, including potential side effects of treatment, were not specifically examined.
INFORMATION:
Peer-reviewed / Meta-analysis / People
NOTES TO EDITORS:
The study was funded by the British Heart Foundation, National Institute for Health Research, Oxford Martin School. It was conducted by researchers from the Blood Pressure Lowering Treatment Triallists' Collaboration.
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
[1] Quotes direct from authors and cannot be found in the text of the Article.
[2] In most people, systolic blood pressure rises steadily with age due to the increasing stiffness of arteries, long-term build-up of plaque, and an increased incidence of cardiac and vascular disease. However, either an elevated systolic or an elevated diastolic blood pressure reading may be used to make a diagnosis of high blood pressure.
IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00590-0/fulltext
BOSTON - After patients with cancer undergo surgery to remove a tumor and sometimes additional chemotherapy, tools are used to identify patients at highest risk of recurrence. Non-invasive tools to detect microscopic disease are of especially high value. In a new study published in END ...
Researchers from the HSE International Laboratory for Supercomputer Atomistic Modelling and Multi-scale Analysis, JIHT RAS and MIPT have compared the performance of popular molecular modelling programs on GPU accelerators produced by AMD and Nvidia. In a paper published by the International Journal of High Performance Computing Applications, the scholars ported LAMMPS on the new open-source GPU technology, AMD HIP, for the first time.
The scholars thoroughly analysed the performance of three molecular modelling programs - LAMMPS, Gromacs and OpenMM - on GPU ...
A new study led by University of Minnesota astrophysicists shows that high-energy light from small galaxies may have played a key role in the early evolution of the Universe. The research gives insight into how the Universe became reionized, a problem that astronomers have been trying to solve for years.
The research is published in The Astrophysical Journal, a peer-reviewed scientific journal of astrophysics and astronomy.
After the Big Bang, when the Universe was formed billions of years ago, it was in an ionized state. This means that the electrons and protons floated freely throughout space. As the Universe ...
In August 2016 a massive storm on par with a Category 2 hurricane churned in the Arctic Ocean. The cyclone led to the third-lowest sea ice extent ever recorded. But what made the Great Arctic Cyclone of 2016 particularly appealing to scientists was the proximity of the Korean icebreaker Araon.
For the first time ever, scientists were able to see exactly what happens to the ocean and sea ice when a cyclone hits. University of Alaska Fairbanks researchers and their international colleagues recently published a new study showing that sea ice declined ...
Older adults were significantly affected by isolation and stress during Oregon's initial COVID-19 lockdown last spring, but they were also able to find connection and meaning in community, new hobbies and time for themselves, a recent Oregon State University study found.
If resilience is understood as the ability to see positives in the midst of a negative situation, then many of the study's participants demonstrated resilience during that time, the researchers said.
"A lot of times we think about resilience as a personality trait, and it's true that there are some qualities that may help people experience that. But in the end, resilience is something that is shared," said Heidi Igarashi, ...
DALLAS, April 29, 2021 – Last Friday, the Centers for Disease Control and Prevention (CDC) and the U.S. Food & Drug Administration (FDA) lifted the pause in administration of the Johnson & Johnson (Janssen) COVID-19 vaccine in the U.S. The temporary pause was due to reports of a serious condition called cerebral venous sinus thrombosis (CVST), which refers to blood clots in the brain’s veins - not in the arteries, as is the case for most strokes - in combination with thrombocytopenia (low blood platelet count). CVST and thrombocytopenia together is called thrombosis-thrombocytopenia syndrome (TTS). When TTS is linked to receiving a COVID-19 vaccine, it is called vaccine-induced immune thrombotic thrombocytopenia ...
Tomorrow's cutting-edge technology will need electronics that can tolerate extreme conditions. That's why a group of researchers led by Michigan State University's Jason Nicholas is building stronger circuits today.
Nicholas and his team have developed more heat resilient silver circuitry with an assist from nickel. The team described the work, which was funded by the U.S. Department of Energy Solid Oxide Fuel Cell Program, on April 15 in the journal Scripta Materialia.
The types of devices that the MSU team is working to benefit -- next-generation fuel cells, high-temperature semiconductors and solid oxide electrolysis cells -- could have ...
New research indicates that the computer-based models currently used to simulate how Earth's climate will change in the future underestimate the impact that forest fires and drying climate are having on the world's northernmost forests, which make up the largest forest biome on the planet. It's an important understanding because these northern forests absorb a significant amount of Earth's carbon dioxide.
The finding, reached by studying 30 years of the world's forests using NASA satellite imaging data, suggests that forests won't be able to sequester as much carbon ...
In a novel effort to combat COVID-19 misinformation, a group of women researchers, including nurse scientists from the University of Pennsylvania School of Nursing (Penn Nursing), launched the Dear Pandemic social media campaign in March 2020. It delivers curated, comprehensive, and timely information about the COVID-19 pandemic in a question-and-answer format. Complex topics such as COVID-19 aerosol transmission, risk reduction strategies to avoid infection, and excess mortality are explained in common language and shared widely.
Now with more than 100,000 followers and accounts on Facebook, ...
FINDINGS
A UCLA-led study shows that physicians frequently order preventive medical services for adult Medicare beneficiaries that are considered unnecessary and of "low value" by the U.S. Preventive Services Task Force -- at a cost of $478 million per year.
The researchers analyzed national survey data over a 10-year period, looking specifically at seven preventive services given a "D" rating by the task force, and discovered that these services were ordered more than 31 million times annually.
BACKGROUND
The U.S. Preventive Services Task Force, an independent panel appointed by the Department of Health and Human Services, makes recommendations on the value of clinical preventive ...
